Weâre excited to welcome Saira Sheikh, M.D., to Pascack Valley Medical Group. Dr. Sheikh is an internal medicine physician committed to providing high-quality, patient-centered care.
Background: Self-monitoring of dietary behaviors is typically a central component of behavioral weight loss programs, and it is widely recognized for its effectiveness in promoting healthy behavior changes and improving health outcom...
First-of-its-kind Breast Cancer Research Study Explores the Impact of Weight Loss Drugs on Recurrence
New research suggests that lycopene, which gives fruits like tomatoes and watermelons their bright red color, supports healthy liver functioning and may help prevent weight gain.
Chulalongkorn University, through its Faculty of Medicine and ...
Monell Center investigators identified that GLP-1R agonists, a class of drugs currently used to treat type-2 diabetes and obesity, as a promising therapeutic for managing the metabolic complications associated with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments. They used a genetically engineered mouse model of BBS that displayed the hallmark features of the condition.
Body mass index, that frequently used barometer of health, may not be as accurate as we might believe.
The April issue of the Journal of the American College of Surgeons (JACS), which includes research presented at the Southern Surgical Association 136th Annual Meeting, features new findings.
Gastric bypass is the most clinically and cost effective form of interventional surgery for people living with severe obesity, reveals landmark research. The new University of Bristol-led trial, funded by the National Institute for Health and Care Research (NIHR), is published today [31 March] in the Lancet Diabetes & Endocrinology journal.
A large majority of older Americans feel that health insurance â including Medicare â should cover anti-obesity medications, according to a new study. And more than half of older adults who meet criteria for obesity say theyâre interested in trying one of these drugs to manage their weight.
Popular prescription weight-loss drugs called GLP-1 receptor agonists are now frequently used by type 1 diabetes patients, despite limited data on the drugsâ safety and effectiveness in this patient population, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
Donât miss NUTRITION 2025, the annual flagship meeting of the American Society for Nutrition, to be held May 31âJune 3 in Orlando. Get an up-close view of the latest nutrition science findings, opportunities and debates, with more than 1,500 original research studies being presented at this yearâs event.
20240326113011.png&width=400&height=400){kind=logo}
Researchers have âpaintedâ GLP-1 receptor agonists onto antibodies through a reaction that happens inside the body. In animal models, a single dose worked better and lasts longer than currently administered dosages. They will present their results at ACS Spring 2025.
Los investigadores han «pintado» los agonistas del receptor del GLP-1 en anticuerpos a través de una reacción que se produce dentro del organismo. En modelos animales, una sola dosis actuó mejor y duró mås que las dosis administradas en la actualidad. Presentarån sus resultados en el encuentro de primavera de 2025 de la ACS.
Does your partner keep leaving for the guest room because of your snoring? You could have sleep apnea. A Penn State Health sleep medicine specialist explains the serious health effects of this often-overlooked condition â and the treatments that can help you get a restful nightâs sleep.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
